Silobreaker.com    Log In
   My Page    Help   
360° SearchNetworkHot SpotsTrends
 
Advanced Search Options >>
Saturday, November 21, 2009 11:19 PM

Leerink Swann & Co Inc

Type: Company
Name: Leerink Swann & Co Inc
First Reported 11/16/2009 - Updated 11/16/2009 - 1 Documents
Bristol-Myers Squibb Company - Click to view image in its original context
Bristol-Myers Squibb Company
Bristol Readies Baby-Formula Business to Walk on Its Own
Bristol-Myers Squibb filed plans with the SEC this morning to split off its Mead Johnson baby-formula unit to concentrate on its core pharmaceuticals business. While other big drug makers are busy diversifying in an effort to reduce the risks at the ... [WSJ.com: Health Blog - 11/16/2009]
First Reported 11/17/2009 - Updated 11/17/2009 - 1 Documents (in Health)
Leerink Swann Upgrades Alkermes (ALKS) to Outperform; Significant Market Opportunity in Opioid Dependence
Leerink Swann upgrades Alkermes (Nasdaq: ALKS) from Market Perform to Outperform.Leerink analyst says, "Yesterday, ALKS reported positive Phase III results from its Vivitrol in opioid dependence trial. We believe this is positive for the company as it ... [Street Insider - 11/17/2009]
First Reported 11/16/2009 - Updated 11/16/2009 - 1 Documents
Humedica forms scientific advisory board
Health-care informatics firm Humedica has created a scientific advisory board reponsible for advising and guiding the Boston-based firms scientific and clinical direction. Humedicas scientific advisory board includes Paul Bleicher, chief medical officer ... [Mass High Tech - 11/16/2009]
First Reported 11/17/2009 - Updated 11/17/2009 - 1 Documents (in Internet & IT)
Alkermes Inc - Click to view 360-page
Alkermes Inc
Alkermes (ALKS) NewsBite - ALKS Upgraded By Leerink Swann - Zibb....
Company: Alkermes, Inc. (ALKS)Alkermes (ALKS) was upgraded today by analysts at Leerink Swann and the stock is now at $9.03, up $0.85 (10.39%) on volume of 1,231,642 shares traded. The analysts upped ALKS to Outperform from Market Perform. Over the last ... [Zibb - 11/17/2009]
First Reported 11/05/2009 - Updated 11/05/2009 - 2 Documents (in Health)
Incyte Corporation Q3 2009 Earnings Call Transcript
Incyte Corporation (INCY)Q3 2009 Earnings CallNovember 5, 2009 8:30 am ETExecutivesPamela Murphy – Vice President Investor Relations and Corporate CommunicationsPaul Friedman – President and Chief Executive OfficerDave Hastings – Executive Vice President ... [Seeking Alpha - 11/05/2009]
First Reported 11/06/2009 - Updated 11/06/2009 - 1 Documents (in Market News)
Toshiba Corporation - Click to view image in its original context
Toshiba Corporation
Vital Images Inc. Q3 2009 Earnings Call Transcript
Vital Images Inc. (VTAL)ExecutivesMike Carrel – President and Chief Executive OfficerPeter Goepfrich – Chief Financial OfficerAnalystsMichael Cherny – Deutsche Bank SecuritiesRichard Close – Jefferies & CompanySean Wieland – Piper JaffrayGeorge Hill – ... [Seeking Alpha - 11/06/2009]
First Reported 11/06/2009 - Updated 11/06/2009 - 1 Documents
Omnicare, Inc. Q3 2009 Earnings Call Transcript
Anton [ph] – RBC CapitalBrendan Strong – Barclays CapitalA.J. Rice – Soleil SecuritiesJason Gurda – Leerink SwannAsif [ph] – JPMorganSteven Valiquette – UBSAlan Fishman – Thomas Weisel PartnersPresentationOperatorGood morning. My name is Carey, and I ... [Seeking Alpha - 11/06/2009]
First Reported 11/09/2009 - Updated 11/09/2009 - 1 Documents
Leerink Swann Upgrades Merck & Co (MRK) to Outperform; Near-Term Risks Already Factored In
Leerink Swann upgrades Merck & Co (NYSE: MRK) from Market Perform to Outperform.Leerink analyst says, "We are upgrading MRK to Outperform, reflecting our growing comfort that near-term risks (ARBITER 6, Temodar U.S. patent challenge, Remicade/Simponi ... [Street Insider - 11/09/2009]
First Reported 11/09/2009 - Updated 11/09/2009 - 1 Documents (in Internet & IT)
Wall Street Firm Believes Risks are Priced into Merck Shares (MRK)
Home› Dividend Stock NewsCreated by Dividend.comInvestment firm Leerink Swann is out with a note this morning, saying Merck’s (MRK) near-term risks have already been priced in.The company suggests another possible leg down for Zetia/Vytorin in the U.S, ... [Nasdaq - 11/09/2009]
First Reported 11/09/2009 - Updated 11/09/2009 - 1 Documents
Merck’s Mega-Monday Morning
Many analysts, lobbyists and industry executives have been saying for months that healthcare reform would probably end up being a net positive for the drug companies.Presumably with more people being covered, big pharma could make up in volume what it ... [CNBC - 11/09/2009]
First Reported 11/10/2009 - Updated 11/10/2009 - 1 Documents
Javelin Pharmaceuticals, Inc. Q3 2009 Earnings Call Transcript
Javelin Pharmaceuticals, Inc. (JAV)Q3 2009 Earnings CallNovember 10, 2009 8:30 am ETExecutivesMartin J. Driscoll – Chief Executive OfficerStephen J. Tulipano, CPA, MBA – Chief Financial OfficerFrederick E. Pierce, II – Vice President, Investor Relati ... [Seeking Alpha - 11/10/2009]
First Reported 11/12/2009 - Updated 11/12/2009 - 1 Documents
Leerink Says Takeaway From Dendreon's (DNDN) Q3 Report is the Busy Preparations for Provenge
More News related to DNDNMore News related to Analyst CommentsLeerink Swann commented on Dendreon Corporation (Nasdaq: DNDN) saying the Q3 report highlights the busy preparations for the Provenge launch.The firm commented, "DNDN's higher-than-estimated ... [Street Insider - 11/12/2009]

Quotes

...Analysts expect the new study to cause further sales declines as doctors question the drugs' usefulness. "We believe our current model, which assumes a 30% decline in U S Zetia/ Vytorin utilization by 2011, likely represents a worst case impact from ARBITER 6" Leerink Swann analyst Seamus Fernandez wrote in a research note Monday
UPDATE: Merck, Abbott Rise After Cholesterol-Drug Study [CNN Money - 11/16/2009]
...In hindsight, it looks as if the strategic rationale behind the merger might have been flawed. "Management concedes it has not done a good job of communicating the message why the combination of PBM and retail pharmacies makes sense" Leerink Swann's Hill said
After Massive Sell-Off, CVS Gets On-Message [Yahoo! Canada - 11/14/2009]
...But JPMorgan's Chris Schott says in a research note to clients this week, "The key swing factor when considering the potential impact to the (Vytorin/Zetia) cholesterol franchise will be the degree of media focus around the study." We reporters get it from all sides
Merck: Both Sides Now [CNBC - 11/13/2009]

More Content

All (186) | News (171) | Reports (0) | Blogs (15) | Audio/Video (0) | Fact Sheets (0)
sort by: Date | Relevance
No Relief for Genzyme as APB Failure Dents Rena... [BioWorld - 11/19/2009]
Alkermes (ALKS) NewsBite - ALKS Upgraded By Lee... [Zibb - 11/17/2009]
UPDATE 1-Leerink Swann raises Alkermes to outpe... [Forbes.com - 11/17/2009]
Notable Analyst Rating Changes 11/17: XOM, PALM... [Street Insider - 11/17/2009]
Daily State of the Markets: The Buck Stops Where? [Street Insider - 11/17/2009]
Analyst Upgrades for November 17th - Zibb.com [Zibb - 11/17/2009]
Upgrades & Downgrades: Going Palm's Up [Minyanville - 11/17/2009]
Leerink Swann Upgrades Alkermes (ALKS) to Outpe... [Street Insider - 11/17/2009]
Durham’s Addrenex sells for $29M [Biz Journals - 11/16/2009]
Humedica forms scientific advisory board [Mass High Tech - 11/16/2009]
UPDATE: Merck, Abbott Rise After Cholesterol-Dr... [CNN Money - 11/16/2009]
Johnson & Johnson Q3 2009 Earnings Call Tra... [Seeking Alpha - 11/16/2009]
Humedica Forms Scientific Advisory Board [Business Wire UK - 11/16/2009]
Sciele Pharma, a Shionogi Company, to Acquire A... [Business Wire - 11/16/2009]
Insulet Corporation Q3 2008 Earnings Call Trans... [Seeking Alpha - 11/14/2009]
After Massive Sell-Off, CVS Gets On-Message [Yahoo! Canada - 11/14/2009]
Merck: Both Sides Now [CNBC - 11/13/2009]
A New Cholesterol Study Puts Focus on Merck Drugs [New York Times - 11/13/2009]
Cholesterol Study Vital for Merck [New York Times - 11/13/2009]
New Data Could Help Thoratec Device Tap Big Market [Nasdaq - 11/12/2009]
LEO Pharma acquires 100% stake in Peplin - Zibb... [Zibb - 11/12/2009]
Leerink Says Takeaway From Dendreon's (DNDN) Q3... [Street Insider - 11/12/2009]
Market Report -- Short Stories (DNDN) [Briefing.com via MSN Money - 11/12/2009]
Medtronic, Inc. F1Q10 (Qtr End 07/31/09) Earnin... [Seeking Alpha - 11/12/2009]
Reuters Summit-Merck CEO mulls successor after ... [Forbes.com - 11/10/2009]
Analysts speculate on upcoming findings of Zeti... [PSL Group - 11/10/2009]
Javelin Pharmaceuticals, Inc. Q3 2009 Earnings ... [Seeking Alpha - 11/10/2009]
InterMune, Inc. Q3 2009 Earnings Call Transcript [Seeking Alpha - 11/10/2009]
Merck’s Mega-Monday Morning [CNBC - 11/09/2009]
Wall Street Firm Believes Risks are Priced into... [Nasdaq - 11/09/2009]
1 2 3 4 5 6
In Focus
  •  
Seamus Fernandez, Paul Friedman, Rick Wise, [more]
  •  
Amgen Inc, Alkermes Inc, Human Genome Sciences Inc, [more]
  •  
Food and Drug Administration, Harvard Medical School, Financial Industry Regulatory Authority, [more]
  •  
Health Care, Induction, Biotechnology, [more]
  •  
Boston (Massachusetts, United States), Bristol, Chicago, [more]
  •  
United States, Japan, Singapore, [more]
  •  
Medicine, Biology, Internet & IT, [more]
  •  
Pharma & Biotech, Health, Banking & Financial Services, [more]
Street Insider, Seeking Alpha, Briefing.com via MSN Money, [more]
Content Volume
Network
Trends

Blogs

sort by: Date | Relevance
Bristol Readies Baby-Formula Business to Walk o... [WSJ.com: Health Blog - 11/16/2009]
Bristol-Myers Squibb filed plans with the SEC this morning to split off its Mead Johnson baby-formula unit to concentrate on its core pharmaceuticals business. While ...
Top 10 Analyst Upgrades, Downgrades, Initiation... [24/7 Wall St. - 11/02/2009]
These are this Monday’s top ten analyst upgrades, downgrades, and initiations seen from Wall Street research firms: Biogen Idec (NASDAQ: BIIB) Raised to Buy at ...
The Least Helpful Call You Will See Today [Jeff Matthews Is Not Making This Up - 10/21/2009]
The least helpful call you will see today—and there are a number of contestants for that honor, not the least being Leerink Swann’s reduction in price target for ...
Medical Records: Stored in the Cloud, Sold on t... [Wired: Threat Level - 10/19/2009]
When patients visit a physician or hospital, they know that anyone involved in providing their health care can lawfully access their medical records. But unknown ...
Top 10 Analyst Upgrades, Downgrades, Initiation... [24/7 Wall St. - 10/19/2009]
These are ten of the top analyst upgrades, downgrades, and initiations seen early this Monday morning from Wall Street research notes: Accenture (NYSE: ACN) Cut ...
1 2 3

  •  
  •  
  •